scholarly journals Phytochemical Analysis of Ashwagandha (Withania Somnifera) and its Role on Covid-19 –A Qualitative Review

AYUSHDHARA ◽  
2021 ◽  
pp. 3362-3370
Author(s):  
Arvind Kumar Mishra ◽  
S. Pavan Kumar

COVID-19 being a mild to severe respiratory and an infectious disease is caused by a new viral strain named coronavirus 2 (SARS-CoV-2). Though managed with antivirals such as lopinavir, ritonavir and nelfinavir, as well as the antimalarials chloroquine and hydroxychloroquine etc, none of them have provided the promising solution. Amidst these conventional approaches, bioactive natural compounds are being considered due to its good biocompatibility, bioavailability, less toxicity and rich phyto-constituents like phenols, steroids and flavonoid molecules etc. Ayurvedic system of medicine is the Ancient medicine that is being practiced since 5000yrs ago and Ashwagandha or Withania somnifera is being used as a rasayana in traditional medicine systems like Ayurveda, Unani, and Siddha. This has been known for its therapeutic benefits since long period including anticancer properties, neuro-protective, cardio-protective, hepato-protective, anti-inflammatory, anti-diabetic, antimicrobial, anti-arthritic, antistress/adaptogenic, chemo-/radiation sensitizing and immuno-modulatory properties etc. Currently Ashwagandha has been extensively studied using molecular docking approaches on Covid-19 due to its immuno-modulatory properties and Withania somnifera could be developed as a therapeutic agent against COVID-19 for both management and prevention.

2018 ◽  
Vol 25 (20) ◽  
pp. 2292-2303 ◽  
Author(s):  
Negar Talaei Zanjani ◽  
Monica Miranda Saksena ◽  
Fariba Dehghani ◽  
Anthony L. Cunningham

Hemocyanins are large and versatile glycoproteins performing various immunological and biological functions in many marine invertebrates including arthropods and molluscs. This review discusses the various pharmacological applications of mollusc hemocyanin such as antiviral activity, immunostimulatory and anticancer properties that have been reported in the literature between the years 2000 and 2016. Emphasis is placed on a better mechanistic understanding of hemocyanin as a therapeutic agent. Elucidation of the mechanism of action is essential to improve the clinical efficacy and for a better understanding of some endogenous immunological functions of this complex glycoprotein.


Antioxidants ◽  
2020 ◽  
Vol 9 (9) ◽  
pp. 857
Author(s):  
Inyong Jung ◽  
Hyerin Kim ◽  
Seongcheol Moon ◽  
Hyuk Lee ◽  
Bonglee Kim

Salvia miltiorrhiza Bunge (S. miltiorrhiza) is a medicinal herb that has been used for the treatment for various diseases such as cardiovascular and cerebrovascular diseases in East Asia including Korea. Considering its extensive usage as a therapeutic agent for multiple diseases, there is a need to review previous research regarding its therapeutic benefits and their mechanisms. Therefore, we searched PubMed and PubMed Central for articles reporting its therapeutic effects on certain disease groups including cancers, cardiovascular, liver, and nervous system diseases. This review provides an overview of therapeutic benefits and targets of S. miltiorrhiza, including inflammation, fibrosis, oxidative stress, and apoptosis. The findings on multi-functional properties of S. miltiorrhiza discussed in this article support the efficacy of S. miltiorrhiza extract on various diseases, but also call for further research on the multiple mechanisms that mediate its therapeutic effects.


2015 ◽  
Vol 177 ◽  
pp. 155-161 ◽  
Author(s):  
Franklin John ◽  
Jinu George ◽  
Mrinal Srivastava ◽  
P. A. Hassan ◽  
V. K. Aswal ◽  
...  

Nonhomologous end joining (NHEJ) of DNA double strand breaks (DSBs) inside cells can be selectively inhibited by 5,6-bis-(benzylideneamino)-2-mercaptopyrimidin-4-ol (SCR7) which possesses anticancer properties. The hydrophobicity of SCR7 decreases its bioavailability which is a major setback in the utilization of this compound as a therapeutic agent. In order to circumvent the drawback of SCR7, we prepared a polymer encapsulated form of SCR7. The physical interaction of SCR7 and Pluronic® copolymer is evident from different analytical techniques. The in vitro cytotoxicity of the drug formulations is established using the MTT assay.


2020 ◽  
Vol 13 (3) ◽  
pp. 322-332
Author(s):  
B. Anita

From time immemorial plants have been used as potent therapeutic agents to treat various ailments in the Siddha and Ayurveda streams of medicine. Plants are rich sources of flavonoids, alkaloids, terpenoids and other related polyphenols. One such important plant used for treating heart ailments is Terminalia arjuna. The bark of this plant plays a vital role as cardiac tonic. It also possesses antimicrobial, cytotoxic and antidiabetic properties. The phytochemical activity of the secondary metabolites present in the bark of T.arjuna has been reported widely. But, the medical uses of leaf extract of the plant have seldom been reported. In this work, the ethanolic extract of leaf of T. arjuna has been analysed for the presence of different phytochemicals using FTIR, UV-Visible and GC-MS spectroscopic methods. The various functional groups present in the leaf extract have been identified initially using FTIR and UV-Vis spectra of leaf extract. Next, GC-MS studies revealed the complete structure of the twelve major phytoconstituents that were present in the leaf extract. In the next stage of the study, the therapeutic effect of the extract as potent anti-bacterial and antifungal agent has been studied. The presence of a flavonoid and ester groups in the leaf extract as revealed by the GC-MS analysis and the potential anti-fungal and anti-baterial activity of the extract shows that leaf extract of Terminalia arjuna has a great potential to be used as a therapeutic agent.


2021 ◽  
Vol 2021 ◽  
pp. 1-10 ◽  
Author(s):  
Atefeh Satari ◽  
Sorayya Ghasemi ◽  
Solomon Habtemariam ◽  
Shirin Asgharian ◽  
Zahra Lorigooini

Rutin is a unique antioxidant flavonoid that is mainly found in fruit, vegetables, cereals, and many other plant-based human diets. This review aims to highlight the in vitro anticancer properties of rutin including combination therapeutic strategies. Literature resources were gathered through PubMed, Scopus, Web of Science, and Google Scholar databases that cover the period of 1995–2021. Rutin is demonstrated to inhibit the proliferation of breast, colon, lung, and prostate cancers and other tumors. Furthermore, rutin alone or in combination with other therapeutic agents has been shown to regulate several signalling pathways involving the Ras/Raf and PI3K/Akt, MAPK, and TGF-β2/Smad2/3Akt/PTEN, etc., which are related to the processes of carcinogenesis and induction of apoptosis. The combination of rutin with other chemotherapy drugs may benefit on prevention of tumor cells by decreasing drug resistance and chemotherapy side effects. Moreover, rutin induces apoptosis synergistically with the therapeutic agent. More in vivo and clinical data are however needed to evaluate the true potential of rutin as an anticancer agent as an adjuvant. The present review highlights the effects of rutin which can be a promising candidate in combination with other antitumor drugs or alone for cancer treatment in vitro. Also, rutin can lead to decrease in drug resistance and chemotherapeutic side effects.


2020 ◽  
Vol 16 (6) ◽  
pp. 738-746
Author(s):  
Vasileios Tsekouras ◽  
Spyridon Kintzios

Background: This review aims to highlight biotechnological techniques applied for the identification, isolation and propagation of mistletoe-derived bioactive compounds and the preclinical evaluation of their anticancer properties. Methods: We undertook a structured search of bibliographic databases to identify and evaluate the literature, regarding biotechnology of mistletoe and malignancy treatment. The selected articles were classified into five modules according to the study design. Results: Firstly, we have provided an overview of the role of biotechnology in plant-derived pharmaceuticals, by reviewing twelve articles. Then, V. album L. botany and a retrospection of the plant pharmaceutical applications are presented from a set of ten articles. Subsequently, mistletoe derived compounds and their anticancer properties are highlighted, throughout sixty-two articles, which emphasized the mechanisms of antitumor action. The next module is referred to as the biosynthesis of mistletoe bioactive compounds, covering nine cases of ‘in vitro’ propagation and genetic manipulation. Finally, fourteen assays regarding mistletoe preparations and preclinical testing for chemosensitivity are presented. Conclusion: Biotechnology provides essential tools for the identification, production and evaluation of anticancer compounds derived from Viscum album L. The preclinical studies indicate the potential use of V. album preparations in chemotherapy but further research is essential for standardizing the therapeutic benefits of mistletoe compounds in the treatment of malignancies.


2021 ◽  
Vol 2 (1) ◽  
pp. 200-207
Author(s):  
Mark Anthony Tingson ◽  
Alma Politano

The present study was undertaken to confirm the phytochemical contents of Saekan (Mollugo oppositofolia Linn.) The plant sample was first confirmed by the Bureau of Plant Industry with a scientific name Mollugo oppositofolia Linn. and a common name Saekan/Papait/Salsalida plant under the family Aizoaceae. The results from a phytochemical analysis of about 500 grams of dried whole plant sample in the Chemistry Laboratory of the Department of Science and Technology Region III (DOST III) Office confirmed that alkaloidal compounds, a phytochemical with antimicrobial, anthelminthic, and antidiarrheal properties were present due to the formation of turbidity or white precipitate using Meyer Test; a reddish-brown layer that turned to blue/purple showed in the Keller-Killiani Test proved the presence of glycosides which has anti-diarrheal properties; and Saponins were found to be in the plant using Froth Test due to a formation of froth which has anthelmintic, antidiarrheal, and anticancer properties.


2000 ◽  
Vol 84 (S1) ◽  
pp. 161-166 ◽  
Author(s):  
Harsharnjit S. Gill ◽  
M. L. Cross

Improved means of cancer prevention and treatment remain key goals of global health programmes. This is particularly true in Western society, where the elderly represent a large proportion of the population, and where the likelihood of tumour development is compounded by risk factors such as poor fibre/high fat diets and environmental pollution. Dietary intervention represents an attractive, non-invasive means of providing anticancer preventative and therapeutic benefits to at-risk individuals. This review focuses on the evidence for anticancer properties of bovine milk and milk-derived components. Evidence of a role for whole milk constituents, as well as purified minor components, in combating tumorigenesis is outlined. Shortcomings in current studies are highlighted, and future opportunities for targeted research to characterize important anticancer properties of milk are discussed.


2016 ◽  
Vol 113 (33) ◽  
pp. 9339-9344 ◽  
Author(s):  
Yi Qu ◽  
Naouel Gharbi ◽  
Xing Yuan ◽  
Jan Roger Olsen ◽  
Pernille Blicher ◽  
...  

Oncogenic mutations of the Wnt (wingless)/β-catenin pathway are frequently observed in major cancer types. Thus far, however, no therapeutic agent targeting Wnt/β-catenin signaling is available for clinical use. Here we demonstrate that axitinib, a clinically approved drug, strikingly blocks Wnt/β-catenin signaling in cancer cells, zebrafish, and Apcmin/+ mice. Notably, axitinib dramatically induces Wnt asymmetry and nonrandom DNA segregation in cancer cells by promoting nuclear β-catenin degradation independent of the GSK3β (glycogen synthase kinase3β)/APC (adenomatous polyposis coli) complex. Using a DARTS (drug affinity-responsive target stability) assay coupled to 2D-DIGE (2D difference in gel electrophoresis) and mass spectrometry, we have identified the E3 ubiquitin ligase SHPRH (SNF2, histone-linker, PHD and RING finger domain-containing helicase) as the direct target of axitinib in blocking Wnt/β-catenin signaling. Treatment with axitinib stabilizes SHPRH and thereby increases the ubiquitination and degradation of β-catenin. Our findings suggest a previously unreported mechanism of nuclear β-catenin regulation and indicate that axitinib, a clinically approved drug, would provide therapeutic benefits for cancer patients with aberrant nuclear β-catenin activation.


Sign in / Sign up

Export Citation Format

Share Document